Ambrosini, Francesca
Falkenbach, Fabian
Budäus, Lars
Steuber, Thomas
Graefen, Markus
Koehler, Daniel
Knipper, Sophie
Maurer, Tobias http://orcid.org/0000-0002-5660-7691
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 25 July 2023
Accepted: 27 September 2023
First Online: 13 October 2023
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: The author Tobias Maurer (T.M.) has a potential/perceived conflict of interest regarding relationships with external parties. Specifically, TM is/was advisor/consultant for ABX (2022–ongoing), Advanced Accelerator Applications International S.A (2020-2021), Astellas (2019), Axiom (2021–ongoing), Blue Earth Diagnostics (2019), GEMoAb (2020), Novartis (2020–ongoing), ROTOP Pharma (2019–2021), Telix (2020-2022). Moreover, he is/was speaker for Astellas (2012–ongoing), Bayer (2020–2022), Janssen-Cilag (2023), Phillips (2019), and Sanofi-Aventis (2014–2019).